That’s why experts are cheering the US Food and Drug ... trials showed a new drug Cobenfy could address positive and negative ...

Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

The US FDA has approved a new drug, Cobenfy, for treating schizophrenia in adults. This is a first new class for medication ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...

In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community ...

The successful commercialization of acoramidis could establish BridgeBio as a key player in the ATTR-CM market, significantly improving its path to profitability. BridgeBio's valuation relies on the ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...